Categories

The strong culture of Myriad is a critical component of our company’s success.  Today, we are launching an Employee Spotlight!  It’s a way for Myriad to introduce the world to the wonderful people that make our company so fantastic. The Myriad Employee Spotlights will be promoted via social media and will highlight several employees over…

Continue Reading

We are very excited to announce the launch of EndoPredict in the U.S.! This second-generation test provides more accurate 10-year recurrence risk for patients diagnosed with ER+ HER2- Early-Stage Breast Cancer. Read more here: https://myriad.com/investors/press-release-detail/?newsItemId=1017053 To learn more about EndoPredict, click here: http://endopredictusa.com/

Continue Reading

March is Colon Cancer Awareness Month and it’s a good time to learn about hereditary colon cancer and how to lower the risk of developing cancer. Hereditary colon cancer accounts for five to 10 percent of all colon cancer and is caused by a genetic mutation that is inherited from either parent. Early occurrence (50 years…

Continue Reading

Understanding your risk for hereditary cancer is an important step in preventing cancer. Myriad Genetics has put together this new infographic on the importance of knowing your family history of cancer, so that you can understand your potential risks. Additionally, if you’re looking for more information on cancer prevention, we have a 30-second Hereditary Cancer…

Continue Reading

A variety of fine English foods With Victoria Sponge Cake, clotted crème, and Branston pickle on their lips a small group of colleagues from across Myriad Genetics sat down for High Tea and a conversation with Jerry Lanchbury, Ph.D., Myriad’s accomplished chief scientific officer. High Tea is an English tradition dating back to 1825 (Click…

Continue Reading

One of Myriad’s core values is our passion for patients worldwide and for transforming their lives with our innovative molecular diagnostic tests. That value is personified by Carolyn Dumond, who is our manager of Patient Advocacy and Education. Her untiring work on behalf of patients and their families is evidenced by the numerous advocacy partners…

Continue Reading

EVP for Emerging Products Patrick Burke notes that our research and development model requires us to rely on collaborations with academics and pharmaceutical companies to help find answers to pressing medical questions.

Continue Reading

Dr. Johnathan Lancaster talks about Myriad’s policies on patient privacy and access to their personal genetic test results. “Myriad believes that a patient’s genetic information is private and confidential. Genetic test results can only be shared with the patient, anyone the patient designates or their healthcare provider.”

Continue Reading

CEO Mark Capone talks about Myriad’s 25-year history and our pioneering work in the molecular diagnostics industry, as well as his vision for the future. “We’ve helped 2 million patients over the last 25 years, but we’re just getting started.”

Continue Reading

Six years ago, my doctor told me I had prostate cancer, and the news literally brought me to my knees. To say that I was scared at that moment is a big understatement. Nobody wants to hear the words, “You’ve got cancer,” and there are just no words to describe the devastation I felt. I…

Continue Reading